OBJECTIVES: The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic cerebral injury in a range of experimental settings, and IL-1ra causes a marked reduction of cell death when administered peripherally or at a delay in transient cerebral ischaemia. We report here the first randomised, double blind, placebo controlled trial of recombinant human IL-1ra (rhIL-1ra) in patients with acute stroke. METHODS: Patients within 6 hours of the onset of symptoms of acute stroke were randomised to rhIL-1ra or matching placebo. Test treatment was administered intravenously by a 100 mg loading dose over 60 seconds, followed by a 2 mg/kg/h infusion over 72 h. Adverse events and serious adverse events were recorded for up to 3 months, serial blood samples were collected for biological markers up to 3 months, and 5-7 day brain infarct volume was measured by computed tomography. RESULTS: No adverse events were attributed to study treatment among 34 patients randomised. Markers of biological activity, including neutrophil and total white cell counts, C reactive protein, and IL-6 concentrations, were lower in rhIL-1ra treated patients. Among patients with cortical infarcts, clinical outcomes at 3 months in the rhIL-1ra treated group were better than in placebo treated. CONCLUSIONS: These data suggest that rhIL-1ra is safe and well tolerated in acute stroke. In addition, rhIL-1ra exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. Our findings identify rhIL-1ra as a potential new therapeutic agent for acute stroke.
OBJECTIVES: The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic cerebral injury in a range of experimental settings, and IL-1ra causes a marked reduction of cell death when administered peripherally or at a delay in transient cerebral ischaemia. We report here the first randomised, double blind, placebo controlled trial of recombinant human IL-1ra (rhIL-1ra) in patients with acute stroke. METHODS: Patients within 6 hours of the onset of symptoms of acute stroke were randomised to rhIL-1ra or matching placebo. Test treatment was administered intravenously by a 100 mg loading dose over 60 seconds, followed by a 2 mg/kg/h infusion over 72 h. Adverse events and serious adverse events were recorded for up to 3 months, serial blood samples were collected for biological markers up to 3 months, and 5-7 day brain infarct volume was measured by computed tomography. RESULTS: No adverse events were attributed to study treatment among 34 patients randomised. Markers of biological activity, including neutrophil and total white cell counts, C reactive protein, and IL-6 concentrations, were lower in rhIL-1ra treated patients. Among patients with cortical infarcts, clinical outcomes at 3 months in the rhIL-1ra treated group were better than in placebo treated. CONCLUSIONS: These data suggest that rhIL-1ra is safe and well tolerated in acute stroke. In addition, rhIL-1ra exhibited biological activity that is relevant to the pathophysiology and clinical outcome of ischaemic stroke. Our findings identify rhIL-1ra as a potential new therapeutic agent for acute stroke.
Authors: P Langhorne; D J Stott; L Robertson; J MacDonald; L Jones; C McAlpine; F Dick; G S Taylor; G Murray Journal: Stroke Date: 2000-06 Impact factor: 7.914
Authors: M Shahid Siddique; Helen M Fernandes; Thomas D Wooldridge; John D Fenwick; Piotr Slomka; A David Mendelow Journal: J Neurosurg Date: 2002-04 Impact factor: 5.115
Authors: Stefano G Daniele; Georg Trummer; Konstantin A Hossmann; Zvonimir Vrselja; Christoph Benk; Kevin T Gobeske; Domagoj Damjanovic; David Andrijevic; Jan-Steffen Pooth; David Dellal; Friedhelm Beyersdorf; Nenad Sestan Journal: Nat Rev Neurosci Date: 2021-07-21 Impact factor: 34.870
Authors: Alexander P Reiner; Mark M Wurfel; Leslie A Lange; Christopher S Carlson; Alex S Nord; Cara L Carty; Mark J Rieder; Cindy Desmarais; Nancy S Jenny; Carlos Iribarren; Jeremy D Walston; O Dale Williams; Deborah A Nickerson; Gail P Jarvik Journal: Arterioscler Thromb Vasc Biol Date: 2008-05-01 Impact factor: 8.311
Authors: Kwaku Asare; Beatrice E Gee; Jonathan K Stiles; Nana O Wilson; Adel Driss; Alexander Quarshie; Robert J Adams; Abdullah Kutlar; Jacqueline M Hibbert Journal: Cytokine Date: 2009-11-08 Impact factor: 3.861
Authors: Kristiina Rajamäki; Tommy Nordström; Katariina Nurmi; Karl E O Åkerman; Petri T Kovanen; Katariina Öörni; Kari K Eklund Journal: J Biol Chem Date: 2013-03-25 Impact factor: 5.157